4D Molecular Therapeutics (FDMT)
4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific
4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak business signals • Minimal market impact **Sentiment:** Neutral (50%) **Content type:** Business